SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the “Events & Presentations” page within the Inv ...

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Compa ...

Fiscal Year 2025 Results Presentation, February 24, 2026 Forward-Looking Statements This presentation contains "forward looking statements," all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "vision," " progress," "believe," "anticipate," "plan," "continue," "forward," "goal," "should," "expect," "outlook," "estimate," "next," "encouraging," " aim," and "will," and "initiate" as well as any similar expressio ...

Core Viewpoint - Erasca, Inc. has received a patent for ERAS-4001, a pan-KRAS inhibitor, providing intellectual property protection until at least 2043, which strengthens its position in the RAS-driven cancer market [1][2] Group 1: Intellectual Property and Pipeline - The newly issued U.S. patent enhances the ERAS-4001 program and supports the company's diversified intellectual property strategy in RAS-driven cancers [2] - The patent protection for ERAS-4001 extends through at least 2043, with additional patents pending, providing a robust long-term IP foundation [2] - Initial Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, while data for ERAS-4001 is anticipated in the second half of 2026 [1] Group 2: Product Details - ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor currently being evaluated in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors [3] - Preclinical studies show ERAS-4001 has favorable potency against KRAS G12X mutations and wildtype amplifications, with no activity against HRAS or NRAS wildtype proteins [3] - ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS-1 Phase 1 trial, demonstrating favorable safety and tolerability, with early data showing responses in multiple patients [4] Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company's mission is to "erase cancer" through novel therapies and combination regimens targeting the RAS/MAPK pathway [5]

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical structural var ...

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m. ETLocation: Boston, MA Leerink Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 8:40 a ...

• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform SEATTLE, Feb. 24, 2026 (GLO ...

Core Insights - Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in capital allocation and operational execution to support the company's growth in cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing safe and effective cell therapies for patients with autoimmune diseases and cancers [1][6]. - The company's lead program, AlloNK, is an allogeneic NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [6]. Leadership Appointment - Thad Huston has over 30 years of global leadership experience in finance, commercial strategy, and operations within the pharmaceuticals and biotechnology sectors [2]. - Huston previously served as CFO and COO at Galapagos, leading the company's transition to an oncology-focused cell therapy organization [2]. Inducement Grant - Artiva's Board of Directors approved an employment inducement grant of 220,000 restricted stock units to Mr. Huston, which will vest over four years [3][4]. - The grant is contingent upon the filing of a registration statement to register the shares under Artiva's 2025 Inducement Plan [4][5]. Clinical Development - AlloNK is currently being evaluated in three clinical trials targeting B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease [6]. - The company is preparing to receive feedback from the FDA regarding a potential pivotal trial and plans to share clinical efficacy data in rheumatoid arthritis in the first half of the year [2]. Strategic Positioning - Artiva aims to position itself for sustained growth by leveraging Huston's financial discipline and operational rigor as it approaches key clinical and regulatory milestones [2].

Core Viewpoint - Aktis Oncology, Inc. has received Fast Track designation from the U.S. FDA for its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer who have progressed after prior systemic therapies [1][7] Group 1: Fast Track Designation - Fast Track designation is intended to expedite the development and review of drugs for serious conditions, allowing for more frequent interactions with the FDA and the possibility of rolling submissions for Biologics License Applications [2] - The designation provides Aktis Oncology a unique opportunity to collaborate closely with the FDA to expedite the development of AKY-1189, addressing an unmet medical need in urothelial cancer treatment [3] Group 2: Clinical Trials and Development - Aktis is conducting a multi-site Phase 1b clinical trial (NCT07020117) for AKY-1189, which includes patients with locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors [3] - Preliminary results from Part 1 of the trial are expected to be presented in the first quarter of 2027 [3] Group 3: Technology and Pipeline - Aktis has developed a proprietary miniprotein radioconjugate platform that selectively delivers radioisotopes to targeted tumors, maximizing anti-cancer activity while minimizing exposure to normal tissues [4] - The company’s pipeline includes AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications across various tumor types [5]

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will parti ...